HtrA serine proteases as potential therapeutic targets in cancer

Jeremy Chien, Mara Campioni, Viji Shridhar, Alfonso Baldi

Research output: Contribution to journalReview article

90 Citations (Scopus)

Abstract

The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.

Original languageEnglish (US)
Pages (from-to)451-468
Number of pages18
JournalCurrent Cancer Drug Targets
Volume9
Issue number4
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Serine Proteases
Peptide Hydrolases
Drug Therapy
Neoplasms
Cell Death
Periplasm
Proteins
Therapeutics
Epigenomics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

HtrA serine proteases as potential therapeutic targets in cancer. / Chien, Jeremy; Campioni, Mara; Shridhar, Viji; Baldi, Alfonso.

In: Current Cancer Drug Targets, Vol. 9, No. 4, 01.06.2009, p. 451-468.

Research output: Contribution to journalReview article

Chien, Jeremy ; Campioni, Mara ; Shridhar, Viji ; Baldi, Alfonso. / HtrA serine proteases as potential therapeutic targets in cancer. In: Current Cancer Drug Targets. 2009 ; Vol. 9, No. 4. pp. 451-468.
@article{07d103d8d9e345b3a21fd71132d2f490,
title = "HtrA serine proteases as potential therapeutic targets in cancer",
abstract = "The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.",
author = "Jeremy Chien and Mara Campioni and Viji Shridhar and Alfonso Baldi",
year = "2009",
month = "6",
day = "1",
doi = "10.2174/156800909788486704",
language = "English (US)",
volume = "9",
pages = "451--468",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - HtrA serine proteases as potential therapeutic targets in cancer

AU - Chien, Jeremy

AU - Campioni, Mara

AU - Shridhar, Viji

AU - Baldi, Alfonso

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.

AB - The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=67649305413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649305413&partnerID=8YFLogxK

U2 - 10.2174/156800909788486704

DO - 10.2174/156800909788486704

M3 - Review article

C2 - 19519315

AN - SCOPUS:67649305413

VL - 9

SP - 451

EP - 468

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 4

ER -